3D printing and bioprinting have the potential to transform how drug candidates are tested, how drugs are manufactured, the supply chain, and industry dependence on animal testing.
Cover: 3D printing and bioprinting have the potential to transform how drug candidates are tested, how drugs are manufactured, the supply chain, and industry dependence on animal testing.
Feature: Drug makers are diversifying their portfolios by partnering with technology companies and embracing innovative products such as connected data-gathering medical devices and platforms that collect and analyze patient data.
Facilities and Equipment: As economic pressures and legislated environmental protection measures continue to increase, the pharmaceutical industry is moving to control cost, reduce energy use, and become a better steward of the environment.